| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) (extension) | 0.24 [0.03, 2.28] | | < 1 | | 0% | 1 study (1/-) | 89.2 % | NA | not evaluable | | important | - |
| events or deaths (EFS) | 0.63 [0.43, 0.93] | | < 1 | | 0% | 1 study (1/-) | 99.1 % | NA | not evaluable | | non important | - |
| pCR | 4.41 [0.49, 39.52] | | > 1 | | 96% | 2 studies (2/-) | 90.6 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.25 [0.01, 4.74] | | < 1 | | 0% | 1 study (1/-) | 81.9 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.35 [1.01, 1.80] | | < 1 | | 0% | 1 study (1/-) | 2.2 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 0.88 [0.47, 1.66] | | < 1 | | 0% | 1 study (1/-) | 64.9 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.25 [0.03, 2.00] | | < 1 | | 0% | 1 study (1/-) | 90.3 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 1.26 [0.96, 1.66] | | < 1 | | 0% | 1 study (1/-) | 4.9 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 1.50 [0.16, 14.43] | | < 1 | | 0% | 1 study (1/-) | 36.5 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 2.16 [1.53, 3.05] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 10.08 [0.59, 173.00] | | < 1 | | 0% | 1 study (1/-) | 5.7 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 0.87 [0.36, 2.09] | | < 1 | | 0% | 1 study (1/-) | 62.3 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 1.27 [0.91, 1.77] | | < 1 | | 0% | 1 study (1/-) | 8.1 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 1.40 [0.65, 3.02] | | < 1 | | 0% | 1 study (1/-) | 19.9 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 3.51 [0.43, 28.62] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.50 [0.01, 25.13] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 3.51 [0.43, 28.62] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
| Diabetes TRAE (grade 3-4) | 1.99 [0.09, 44.34] | | < 1 | | 0% | 1 study (1/-) | 33.3 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.71 [0.63, 4.67] | | < 1 | | 0% | 1 study (1/-) | 14.8 % | NA | not evaluable | | non important | - |
| Dysgeusia TRAE (grade 3-4) | 0.50 [0.01, 25.13] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 2.29 [0.94, 5.58] | | < 1 | | 0% | 1 study (1/-) | 3.5 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 1.13 [0.82, 1.57] | | < 1 | | 0% | 1 study (1/-) | 22.9 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 9.06 [0.52, 156.66] | | < 1 | | 0% | 1 study (1/-) | 6.7 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.99 [0.09, 44.34] | | < 1 | | 0% | 1 study (1/-) | 33.3 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 8.04 [0.46, 140.38] | | < 1 | | 0% | 1 study (1/-) | 7.9 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 3.00 [0.15, 59.96] | | < 1 | | 0% | 1 study (1/-) | 23.9 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 9.67 [1.29, 72.54] | | < 1 | | 0% | 1 study (1/-) | 1.4 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.34 [1.13, 4.86] | | < 1 | | 0% | 1 study (1/-) | 1.1 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 2.53 [0.86, 7.45] | | < 1 | | 0% | 1 study (1/-) | 4.6 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.76 [0.57, 1.03] | | < 1 | | 0% | 1 study (1/-) | 96.3 % | NA | not evaluable | | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.99 [0.09, 44.34] | | < 1 | | 0% | 1 study (1/-) | 33.3 % | NA | not evaluable | | non important | - |
| Myositis TRAE (grade 3-4) | 0.50 [0.01, 25.13] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 2.64 [1.01, 6.94] | | < 1 | | 0% | 1 study (1/-) | 2.4 % | NA | not evaluable | | non important | - |
| Nephritis TRAE (grade 3-4) | 7.03 [0.40, 124.15] | | < 1 | | 0% | 1 study (1/-) | 9.4 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 1.06 [0.82, 1.38] | | < 1 | | 0% | 1 study (1/-) | 31.6 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 4.00 [0.21, 75.85] | | < 1 | | 0% | 1 study (1/-) | 18.1 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 1.88 [0.62, 5.72] | | < 1 | | 0% | 1 study (1/-) | 13.2 % | NA | not evaluable | | non important | - |
| Peripheral sensory neuropathy TRAE (grade 3-4) | 1.20 [0.42, 3.43] | | < 1 | | 0% | 1 study (1/-) | 36.8 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.50 [0.16, 14.43] | | < 1 | | 0% | 1 study (1/-) | 36.5 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 4.02 [0.50, 32.22] | | < 1 | | 0% | 1 study (1/-) | 9.7 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 3.51 [0.43, 28.62] | | < 1 | | 0% | 1 study (1/-) | 12.2 % | NA | not evaluable | | non important | - |
| Sarcoidosis TRAE (grade 3-4) | 0.50 [0.01, 25.13] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 15.50 [2.11, 114.09] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 11.10 [0.65, 189.37] | | < 1 | | 0% | 1 study (1/-) | 5.0 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.99 [0.09, 44.34] | | < 1 | | 0% | 1 study (1/-) | 33.3 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 0.50 [0.01, 25.13] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 1.51 [0.59, 3.82] | | < 1 | | 0% | 1 study (1/-) | 19.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| hepatitis (Autoimmune) AE (grade 3-4) | 1.79 [0.06, 54.10] | | < 1 | | 0% | 1 study (1/-) | 37.1 % | NA | not evaluable | | non important | - |
| Abdominal pain AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Alopecia AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.89 [0.12, 6.46] | | < 1 | | 0% | 1 study (1/-) | 54.6 % | NA | not evaluable | | non important | - |
| Arthralgia AE (grade 3-4) | 1.80 [0.16, 20.23] | | < 1 | | 0% | 1 study (1/-) | 31.8 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.44 [0.01, 13.37] | | < 1 | | 0% | 1 study (1/-) | 67.8 % | NA | not evaluable | | non important | - |
| Blood creatinine increased AE (grade 3-4) | 0.05 [0.00, 0.89] | | < 1 | | 0% | 1 study (1/-) | 97.8 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.89 [0.05, 14.46] | | < 1 | | 0% | 1 study (1/-) | 53.2 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 5.49 [0.27, 111.35] | | < 1 | | 0% | 1 study (1/-) | 13.6 % | NA | not evaluable | | non important | - |
| Dry skin AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Epistaxis AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.47 [0.15, 1.45] | | < 1 | | 0% | 1 study (1/-) | 90.6 % | NA | not evaluable | | non important | - |
| Febrile neutropenia AE (grade 3-4) | 1.82 [0.32, 10.20] | | < 1 | | 0% | 1 study (1/-) | 24.9 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 1.79 [0.06, 54.10] | | < 1 | | 0% | 1 study (1/-) | 37.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Hypophysitis AE (grade 3-4) | 1.79 [0.06, 54.10] | | < 1 | | 0% | 1 study (1/-) | 37.1 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 5.49 [0.27, 111.35] | | < 1 | | 0% | 1 study (1/-) | 13.6 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 1.20 [0.26, 5.51] | | < 1 | | 0% | 1 study (1/-) | 40.9 % | NA | not evaluable | | non important | - |
| Infusion-related reaction AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Injury, poisoning and procedure AE (grade 3-4) | 0.89 [0.05, 14.46] | | < 1 | | 0% | 1 study (1/-) | 53.2 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 0.84 [0.45, 1.57] | | < 1 | | 0% | 1 study (1/-) | 70.9 % | NA | not evaluable | | non important | - |
| Myalgia AE (grade 3-4) | 1.82 [0.32, 10.20] | | < 1 | | 0% | 1 study (1/-) | 24.9 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.06 [0.00, 1.05] | | < 1 | | 0% | 1 study (1/-) | 97.2 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.83 [0.45, 1.52] | | < 1 | | 0% | 1 study (1/-) | 72.8 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy AE (grade 3-4) | 0.88 [0.33, 2.33] | | < 1 | | 0% | 1 study (1/-) | 60.2 % | NA | not evaluable | | non important | - |
| Pneumonitis AE (grade 3-4) | 0.89 [0.02, 45.40] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 0.89 [0.05, 14.46] | | < 1 | | 0% | 1 study (1/-) | 53.2 % | NA | not evaluable | | non important | - |
| Stomatitis AE (grade 3-4) | 3.62 [0.16, 81.50] | | < 1 | | 0% | 1 study (1/-) | 21.2 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.44 [0.04, 4.94] | | < 1 | | 0% | 1 study (1/-) | 74.6 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.89 [0.05, 14.46] | | < 1 | | 0% | 1 study (1/-) | 53.2 % | NA | not evaluable | | non important | - |
